secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008492
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma Q1 2022: $256.2M cash runways into 2H2024; three Phase 1b data readouts in 1H2023
--------------------------------------------------------------------------------

- Cash and investments $256.2M as of March 31, 2022; expected to fund operations into 2H2024.
- R&D expenses $16.8M (up $5.1M YoY) driven by advancing ORIC-533, -114, -944; ORIC-101 discontinued.
- G&A expenses $6.4M (up $1.6M YoY) due to higher personnel costs.
- Three Phase 1b trials (ORIC-533 in multiple myeloma; ORIC-114 in EGFR/HER2; ORIC-944 in prostate) targeting initial data in 1H2023.
- PLK4 inhibitor program in lead optimization for TRIM37-amplified breast cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/0000950170-22-008492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/oric-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer